What is Accelus?
Accelus operates as a worldwide leader in expandable spinal implant technology, focusing on the intersection of mechanical innovation and patient-centric surgical outcomes. The company is best known for its Adaptive Geometry platform, which provides versatile solutions for a range of procedures, including transforaminal lumbar interbody fusion (TLIF), posterior lumbar interbody fusion (PLIF), and endoscopic-assisted surgeries. By prioritizing percutaneous and lateral spine approaches, Accelus addresses the critical need for minimally invasive techniques that reduce recovery times and improve long-term patient health. Their market position is defined by a commitment to excellence in spinal hardware, positioning them as a critical partner for healthcare providers seeking to modernize their surgical suites.
How much funding has Accelus raised?
Accelus has raised a total of $32M across 2 funding rounds:
Series D
$12M
Debt
$20M
Series D (2022): $12M with participation from Concord Health Partners
Debt (2024): $20M led by Symbiotic Capital
Key Investors in Accelus
Concord Health Partners
A strategic investment firm focused on the healthcare sector, specializing in identifying and supporting companies that drive innovation in medical services and technology.
Symbiotic Capital
An investment group providing debt and growth capital to companies demonstrating strong market potential and operational scalability.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Accelus?
With the recent influx of $0, Accelus is well-positioned to accelerate its commercial expansion and deepen its research and development pipeline. The company is expected to focus on the broader adoption of its Adaptive Geometry technologies, targeting increased market penetration in both domestic and international clinical settings. Furthermore, the strategic use of debt financing suggests a focus on operational efficiency and the scaling of manufacturing capabilities to meet the rising demand for advanced spinal implants. As the company matures, the focus will likely shift toward long-term clinical validation and the expansion of its product portfolio to address emerging challenges in orthopedic and neurosurgical care.
See full Accelus company page
